Pharmacy

Your Article Summary

See Latest Articles

Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab
International Journal of Hematology, 06/09/09

Ilic I et al. - In a trial to determine the influence of germinal-center B-cell (GCB) and non-GCB phenotypes of diffuse large B-cell lymphoma (DLBCL) on outcome of 92 pts treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like chemotherapy, with or without rituximab, it was shown that pts with immunohistochemically determined GCB-type DLBCL did not have an improved prognosis, irrespective of whether they had received rituximab or not.

• The differentiation between GCB and non-GCB types was arrived at by immunohistochemistry using previously published criteria.
• 39 pts had the GCB and 53 had the non-GCB type of DLBCL.

• 49 pts were treated with rituximab and chemotherapy; 43 were treated with chemotherapy alone.
• The GCB and non-GCB group did not differ in their international prognostic index factors and score, presence of bulky disease, or frequency of rituximab treatment.
• Median follow-up of surviving pts was carried out for 37 mos.
• There was no difference between GCB and non-GCB groups in both overall response rates (67 vs 70%, respectively) and estimated rates of 3-yr event-free (46 vs 49%, respectively) and overall (54 vs 56%, respectively) survival.
• No differences of the outcomes were observed between subgroups treated with or without rituximab.

Today in Chemotherapy/Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Palliative Oncology: Thalidomide
American Journal of Hospice and Palliative Medicine, 10/21/09

Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09

Aspirin use associated with lower colorectal cancer mortality
American Pharmacists Association, 10/14/09

See All of Chemotherapy/Oncology